Abpro Bio Improves Financial Structure via 10:1 Capital Reduction and Paid-in Capital Increase, Narrowing Q1 Operating Loss

10:1 capital reduction (Feb 24, 2026) cut capital from 142.3B to 16.2B won, offsetting deficit of 128.1B won.
Third-party allocation (Mar 31, 2026) raised 4B won; new largest shareholder 'Returns' (12.61%).
Consolidated Q1 sales 7.89B won (down 11% YoY), operating loss 2.26B won (improved from 3.26B won).
Net profit turned positive to 2.07B won due to non-recurring gain of 4.27B won from equity method investment disposal.
Separate debt ratio 14.85%, cash 2.76B won.
Post-report: issued convertible bonds (3.51B won), acquired other company shares (3.31B won).
Pending litigation: 14.8B won deposit refund lawsuit (second trial).